Research programme: antibacterials - Arrow Therapeutics
Alternative Names: A 11259; A 158; A 161; A 20194; A 762; A 764; A-00000762; A-00026158; A-00026161; Antibacterials research programme - Arrow Therapeutics; Dehydroquinate synthase inhibitors research programme - Arrow Therapeutics; DHQS inhibitors - Arrow Therapeutics; Shikimate kinase inhibitors - Arrow Therapeutics; Type I dehydroquinase inhibitors - Arrow TherapeuticsLatest Information Update: 03 May 2004
At a glance
- Originator Arrow Therapeutics
- Class
- Mechanism of Action Dehydroquinate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-positive infections
Most Recent Events
- 03 May 2004 Discontinued - Preclinical for Gram-positive infections in United Kingdom (unspecified route)
- 26 Sep 2003 Data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial Infections antimicrobial activity section
- 13 Jan 2002 Preclinical development for Gram-positive infections in United Kingdom (Unknown route)